139 completed, 22 active not recruiting, 19 recruiting, 10 terminated. 72 Phase 1, 61 Phase 2, 61 Phase 3, 3 Phase 4.
Follow Ono Pharmaceutical Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal Adenocarcinoma ONO-4578, Placebo, Nivolumab - Gastric Cancer, Esophagogastric Junction Cancer | Phase 3 | Not yet recruiting | Ono Pharmaceutical Co., Ltd. | 600 | 2027-02-01 | 2026-09-14 |
| A Trial of ONO-2808 in Participants With the Parkinsonian Subtype of Multiple System Atrophy (MSA-P) ONO-2808, Placebo - Multiple System Atrophy, Parkinson Variant | Phase 3 | Not yet recruiting | Ono Pharmaceutical Co., Ltd. | 486 | 2027-01-01 | 2026-09-17 |
| A Study of DCC-3014 to Evaluate the Efficacy, Safety, and Pharmacokinetics in Subjects With TGCT DCC-3014 - Tenosynovial Giant Cell Tumor | Phase 2 | Not yet recruiting | Ono Pharmaceutical Co., Ltd. | 18 | 2026-10-31 | 2026-09-22 |
| ONO-4915 in Patients With Primary Sjogren's Disease ONO-4915, Placebo - Sjogren's Disease | Phase 2 | Not yet recruiting | Ono Pharmaceutical Co., Ltd. | 60 | 2026-10-01 | 2026-09-16 |
| A Study of ONO-4538HSC in Pediatric Patients With Malignant Solid Tumors and in Patients With Epithelioid Sarcoma. ONO-4538HSC - Pediatric Malignant Solid Tumor and Epithelioid Sarcoma | Phase 1 / Phase 2 | Recruiting | Ono Pharmaceutical Co., Ltd. | 50 | 2026-09-15 | 2026-10-06 |
| A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ONO-6414 Administered Orally in Healthy Adult Participants and Patients With Active Ulcerative Colitis ONO-6414, Placebo - Ulcerative Colitis (UC) | Phase 1 | Recruiting | Ono Pharmaceutical Co., Ltd. | 90 | 2026-08-20 | 2026-09-09 |
| Study of DCC-2618 in Patients With GIST After at Least 3 Prior Treatments DCC-2618 - Gastrointestinal Stromal Tumors | Phase 1 | Recruiting | Ono Pharmaceutical Co., Ltd. | 10 | 2026-07-07 | 2026-07-20 |
| A Study of ONO-7429 in Participants With Unresectable Advanced or Recurrent Solid Tumors ONO-7429 - Solid Tumors | Phase 1 | Recruiting | Ono Pharmaceutical Co., Ltd. | 80 | 2026-06-19 | 2026-08-26 |
| IGNITE: Study of Tirabrutinib vs Rituximab and Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) Tirabrutinib, Rituximab, Temozolomide - Relapsed/Refractory Primary Central Nervous System Lymphoma | Phase 3 | Recruiting | Ono Pharmaceutical Co., Ltd. | 132 | 2026-06-12 | 2026-10-28 |
| A Study to Evaluate the Safety, Efficacy, and PK of ONO-2017 in Japanese Patients With POS 2 to 17 Year Olds Cenobamate (tablet) for 12 to < 18 year olds, Cenobamate (syrup) for 2 to < 18 year olds - Partial Epilepsy | Phase 3 | Recruiting | Ono Pharmaceutical Co., Ltd. | 20 | 2026-06-10 | 2026-10-09 |
| A Study of ONO-3310 in Healthy Adult Male Subjects and Chronic Kidney Disease Patients With Type 2 Diabetes Mellitus ONO-3310, Placebo - Type2 Diabetes Mellitus, Chronic Kidney Disease | Phase 1 | Recruiting | Ono Pharmaceutical Co., Ltd. | 120 | 2026-06-02 | 2026-06-08 |
| INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV) Sapablursen, Placebo - Polycythemia Vera | Phase 3 | Recruiting | Ono Pharmaceutical Co., Ltd. | 250 | 2026-05-25 | 2026-10-29 |
| A Retrospective Observational Study of Nivolumab in Combination With Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC Patients: Real-World Experience in Taiwan (NEOREAL) Non Small Cell Lung Cancer NSCLC | Recruiting | Ono Pharmaceutical Co., Ltd. | 100 | 2026-03-20 | 2026-05-20 | |
| First-Line Nivolumab Plus Ipilimumab in Unresectable Hepatocellular Carcinoma (J-PROMISE) Nivolumab plus ipilimumab - Unresectable Hepatocellular Carcinoma | Recruiting | Bristol-Myers Squibb | 200 | 2026-03-05 | 2026-07-01 | |
| ONO-4538 Study in Patients With Richter's Transformation ONO-4538 - Richter's Transformation | Phase 2 | Recruiting | Ono Pharmaceutical Co., Ltd. | 14 | 2025-11-19 | 2026-02-13 |
| A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer ONO-4578, Opdivo®, Oxaliplatin - Colorectal Cancer | Phase 2 | Recruiting | Ono Pharmaceutical Co., Ltd. | 144 | 2025-11-18 | 2026-07-16 |
| A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants Tirabrutinib - Primary Central Nervous System Lymphoma (PCNSL) | Phase 1 | Completed | Ono Pharmaceutical Co., Ltd. | 40 | 2025-10-01 | 2026-06-26 |
| A Study of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease Dementia ONO-2020, Placebo - Agitation Associated With Alzheimer's Disease Dementia | Phase 2 | Recruiting | Ono Pharmaceutical Co., Ltd. | 90 | 2025-05-01 | 2026-09-25 |
| A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease ONO-2020, Placebo - Alzheimer Disease | Phase 2 | Completed | Ono Pharmaceutical Co., Ltd. | 260 | 2025-04-24 | 2026-10-22 |
| A Study of ONO-7428 in Participants With Unresectable Advanced or Recurrent Solid Tumors ONO-7428 - Solid Tumor, NSCLC | Phase 1 | Active not recruiting | Ono Pharmaceutical Co., Ltd. | 35 | 2025-04-21 | 2026-08-05 |
Showing 20 of 199. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (10) · Stomach Neoplasms (10) · Carcinoma, Renal Cell (7) · Neoplasms (7) · Colorectal Neoplasms (6) · Diabetes Mellitus, Type 2 (6) · Arthritis, Rheumatoid (5) · Carcinoma, Hepatocellular (5) · Pancreatic Neoplasms (5) · Recurrence (5) · Urinary Bladder, Overactive (5) · Alzheimer Disease (4) · Melanoma (4) · Osteoporosis (4) · Brain Neoplasms (3)
Nivolumab (79) · Ipilimumab (22) · Oxaliplatin (15) · Fluorouracil (14) · Cisplatin (11) · Leucovorin (11) · Capecitabine (10) · tirabrutinib (9) · Bevacizumab (8) · Carboplatin (8) · Gemcitabine (8) · Cetuximab (7) · Abatacept (5) · Docetaxel (5) · Irinotecan (5)
Japan (139) · United States (63) · United Kingdom (43) · South Korea (35) · Spain (35) · Taiwan (35) · France (34) · Italy (34) · Canada (31) · Germany (31) · Australia (27) · Poland (27) · Belgium (24) · Brazil (24) · Netherlands (22)
Project Leader (50) · Project Leader, Development Planning (9) · Mitsunobu Tanimoto (6) · Mikio Nishii (3) · Tomohiro Kuwayama (3) · Drug Development Division (2)
PMID 29158363, PMID 31992108, PMID 32691060, PMID 35383114, PMID 36852452, PMID 37146227, PMID 38383458, PMID 19101754, PMID 19264155, PMID 20718754, PMID 22658127, PMID 23547081, PMID 23784548, PMID 24308791, PMID 24590637, PMID 24843649, PMID 26406148, PMID 26446770, PMID 26542378, PMID 27248633, PMID 27283863, PMID 27444660, PMID 27649982, PMID 27718784, PMID 28131785, PMID 28262413, PMID 28410865, PMID 28434648, PMID 28636851, PMID 28651929, PMID 28891423, PMID 28939066, PMID 28993052, PMID 29119276, PMID 29260460, PMID 29562145, PMID 29658845, PMID 29884413, PMID 30170630, PMID 30215677, PMID 30348216, PMID 30486889, PMID 30566590, PMID 30658932, PMID 30892987, PMID 30944020, PMID 30972702, PMID 31039807, PMID 31176752, PMID 31195357
2016 (11), 2015 (8), 2017 (5), 2014 (3), 2025 (2), 2018 (1), 2019 (1), 2023 (1)